The cytoplasmic trafficking of docosahexaenoic acid (DHA), a cognitively beneficial fatty acid, across the blood-brain barrier (BBB) is governed by fatty acid-binding protein 5 (FABP5). Lower levels of brain DHA have been observed in Alzheimer's disease (AD), which is associated with diminished BBB expression of FABP5. Therefore, up-regulating FABP5 expression at the BBB may be a novel approach for enhancing BBB transport of DHA in AD. DHA supplementation has been shown to be beneficial in various mouse models of AD, and therefore, the aim of this study was to determine whether DHA has the potential to up-regulate the BBB expression of FABP5, thereby enhancing its own uptake into the brain. Treating human brain microvascular brain endothelial (hCMEC/D3) cells with the maximum tolerable concentration of DHA (12.5 lM) for 72 h resulted in a 1.4-fold increase in FABP5 protein expression.
Alzheimer's disease (AD) is associated with brain extracellular deposition of beta amyloid (Ab) plaques, intracellular neurofibrillary tangles formed from intraneuronal accumulation of hyperphosphorylated tau, and a host of inflammatory events (Dekosky 2001; Selkoe 2001; Imbimbo et al. 2005; Querfurth and Laferla 2010) . In addition, the levels of the cognitively beneficial docosahexaenoic acid (DHA) are significantly reduced in human post-mortem AD brains (S€ oderberg et al. 1991; Corrigan et al. 1998; Prasad et al. 1998; Lukiw et al. 2005) . DHA is a polyunsaturated fatty acid (PUFA) that is neuroprotective, and has been demonstrated to alleviate Ab load, reduce phosphorylation of tau, and relieve neuroinflammation (Oksman et al. 2006; Green et al. 2007; Pan et al. 2015a) . Epidemiological studies suggest that consumption of a diet high in n-3 PUFA/DHA content is associated with a lower AD risk (Kalmijn et al. 1997; Barberger-Gateau et al. 2002 Laitinen et al. 2006) , and mounting evidence suggests that a low dietary DHA intake is a risk factor for AD (Loef and Walach 2013) . Therefore, dietary DHA supplementation has attracted much attention as a possible strategy for improving cognitive function in people with AD. Dietary DHA supplementation (6-month intervention) reduced Ab plaque burden by 40-50% in Tg2576 mice (a mouse model over-expressing Ab) (Lim et al. 2005 ) and 9 months of a similar intervention reduced brain levels of Ab by approximately 50% in 3xTg mice (a mouse model with both amyloid and tau pathology) (Green et al. 2007) . In APP/PS1 mice (an AD mouse model over-expressing Ab), 4-month DHA supplementation decreased the number of activated microglia in the hippocampus (Oksman et al. 2006) , supporting the antiinflammatory effects of DHA.
The brain has a limited ability to synthesize its own DHA, and therefore, plasma-derived DHA has to be transported across the blood-brain barrier (BBB). Fatty acid-binding protein 5 (FABP5) is an intracellular protein expressed in brain microvascular endothelial cells, involved in the transport of DHA across the BBB (Pan et al. 2015b) . Reduced BBB expression of FABP5 has been recently reported in a mouse model of AD, and this was associated with reduced BBB trafficking of DHA and diminished brain DHA levels (Pan et al. 2018) . Approaches which increase the BBB expression of FABP5 may therefore restore brain DHA levels in AD. The peroxisome proliferator-activated receptor (PPAR) pathway is one of the recognized signaling pathways regulating FABP expression in hepatocytes (Rogue et al. 2010) . Interestingly, fatty acids are natural ligands of PPARs, and could subsequently up-regulate FABP via PPAR activation. Once fatty acids permeate through cell membranes, they are thought to bind to FABP in a ligand-specific manner. The binding of fatty acids to FABP stabilizes its nuclear localization signal, and the FABP-fatty acid complex subsequently enters the nucleus to activate PPAR (Armstrong et al. 2014) . The activation of PPAR thereafter alters the expression of FABP, though the expression of other genes could also be affected (Rogue et al. 2010) . Interestingly, FABPs and PPARs interact in a receptor-and ligandselective manner. For example, FABP4 directs ligands to PPARc, whereas FABP5 directs ligands to PPARb/d (Tan et al. 2002) . In addition, FABP1 and 2 can differentially modulate the activation of PPARa in a ligand-selective manner (Hughes et al. 2015) .
Spinal cord FABP5 gene expression elevated twofold in rats fed a DHA-enriched diet for 8 weeks (Figueroa et al. 2016) . Therefore, DHA has the potential to up-regulate BBB expression of FABP5 and help to facilitate its own transport across the BBB. Given all the available evidence, this study investigated the impact of DHA dietary supplementation on FABP5 expression at the BBB using both in vitro and in vivo approaches. In vitro experiments were first performed to assess the effect of DHA on FABP5 expression in immortalized human brain microvascular endothelial (hCMEC/D3) cells. As demonstrated in a previous study, only polyunsaturated fatty acids with a cis-conformation can stabilize the nuclear localization signal of FABP5 (Armstrong et al. 2014) and subsequently activate the PPARb/d pathway to enhance FABP5 expression (in a non-BBB system) (Morgan et al. 2010) , and therefore oleic acid (OA) treatment was included in this study to confirm such a finding at the BBB. The BBB expression of FABP5 was also measured in C57BL/6 mice fed a DHA-enriched diet and a control diet for 21 days. This treatment duration was determined from previous dietary intervention studies (2-6 weeks), where an increase in FABP5 (Hoekstra et al. 2006 ) and FABP7 (Elsherbiny et al. 2015) was observed with dietary fatty acids. In addition, the impact of this dietary intervention on the BBB transport of exogenous DHA and brain levels of DHA was investigated. The BBB transport of 14 C-DHA was also studied using primary mouse brain microvascular endothelial cells seeded on a transwell system.
Materials and methods

Materials
DNase I and collagenase were purchased from Thermofisher (Rockford, IL, USA). Dulbecco's modified Eagle medium (DMEM), phosphate-buffered saline (PBS), bovine serum albumin (BSA), OA, Supelco â 37-component FAME mix, methyl nonadecanoate, sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate, monosodium dihydrogen orthophosphate, glucose, dimethyl sulfoxide (DMSO) and thiazolyl blue tetrazolium bromide (MTT) were purchased from SigmaAldrich (St. Louis, MO, USA). 14 C-DHA was purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA), and DHA was obtained from Cayman Chemicals (Ann Arbor, MI, USA). The EBM-2 basal media was supplemented with EGM-2 Endothelial Cell Growth Medium-2 BulletKit as per the manufacturer's instructions (Lonza, Walkersville, MD, USA) to make the complete growth media for primary mouse brain microvascular endothelial cells (MBECs). To make the growth media for hCMEC/ D3 cells, EBM-2 basal media was supplemented with vascular endothelial growth factor (0.025% v/v), insulin-like growth factor 1 (0.025% v/v), epidermal growth factor (0.025% v/v), basic fibroblast growth factor (0.1% v/v), hydrocortisone (0.01% v/v), ascorbic acid (0.01% v/v), fetal bovine serum (0.1% v/v) (available from the BulletKit), HEPES (1 M, pH 7.4, 1% v/v), and penicillinstreptomycin (1% v/v) (purchased from Sigma-Aldrich). Pierce IP lysis buffer was purchased from Thermo Fisher Scientific (Rockford, IL, USA). Rabbit anti-FABP5 polyclonal antibody and mouse anti-b-actin antibody were purchased from Abcam (Cambridge, MA, USA). The goat anti-rabbit and goat anti-mouse secondary antibodies were obtained from (LI-COR Biosciences, Lincoln, NE, USA).
hCMEC/D3 cell viability assays
The hCMEC/D3 cell line (research resource identifiers:CVCL_ U985) was obtained from Pierre-Olivier Couraud (INSERM, France), and cultured according to published methods (Pan et al. 2015b ). This cell line was not listed as a commonly misidentified cell line by the International Cell Line Authentication Committee. The hCMEC/D3 cells are immortalized human brain microvascular endothelial cells regularly used to analyze BBB transporter expression, and therefore used in this study to investigate the impact of DHA on FABP5 expression at the BBB. OA was included as a negative control. To determine the highest concentration of DHA and OA tolerated by hCMEC/D3 cells for a given treatment duration, MTT cell viability assays were performed. The cells (passage 32) were seeded in 96 well plates until they reached 70% confluency and treated with DHA or OA at 0-500 lM for 24-72 h. Ethanol was used to solubilize fatty acids in the serum-containing culture media, and the culture media containing 0.1% v/v ethanol was used for the control wells. Free fatty acids are primarily bound to serum albumin under physiological conditions (Spector 1975) , and the albumin concentration in the culture media is estimated to be 35 lM (Gstraunthaler 2003) . Therefore, the culture media was supplemented with BSA (for fatty acid treatment concentration > 35 lM), achieving an approximately 1 : 1 fatty acid/albumin molar ratio in this study, where all free fatty acids would bind to albumin. Immediately after the fatty acid treatment, cells were rinsed with PBS twice and incubated with MTT reagent (0.05% w/v) in DMEM for 4 h at 37°C. At the end of the 4 h incubation, the MTT reagent was removed and replaced with DMSO to dissolve any formazan crystals that had formed. The absorbance of the resulting DMSO solution was measured at 540 nm wavelength with an EnSpire â multimode plate reader (PerkinElmer, Boston, MA, USA).
The absorption of the treated wells was normalized by the average absorption of the control wells, and data were presented as % viable cells.
Detection of FABP5 mRNA and protein expression in hCMEC/D3 cells following fatty acid treatment hCMEC/D3 cells were seeded in six-well plates to reach 70% confluency and treated with 50 lM DHA or OA for 24 h, 12.5 lM DHA for 48 or 72 h (i.e., maximum tolerated concentrations according to the MTT assay). Total RNA from hCMEC/ D3 cells was isolated using an RNeasy Plus Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol. The iScript TM One-Step RT-PCR Kit (Bio-Rad, Hercules, CA, USA) and Taqman â primer/probes (Thermofisher) were used for PCR reactions in a CFX96 system (Bio-Rad) as previously described (Pan et al. 2015b) . The threshold cycles (C t ) were calculated automatically using the CFX manager software. To determine relative gene expression between control and fatty acid-treated cells, the fold-change method (2 ÀDDCt ) was employed using Equations 1 and 2, with glyceraldehyde 3-phosphate dehydrogenase and b-actin used as reference genes. The geometric mean of the C t values for the two reference genes (C t (reference genes) ) was used for DC t calculation.
To detect FABP5 protein levels by western blotting, treated hCMEC/D3 cells were lysed for 30 min at 4°C using Pierce IP lysis buffer, supplemented with the cOmplete TM Protease Inhibitor Cocktail. To remove cell debris, the lysate was centrifuged at 4°C for 10 min at 14 000 g, the supernatant was collected and the total protein count was determined using bicinchoninic acid assay (Thermo Fisher Scientific) according to manufacturer's protocol. Aliquots of 20 lg total protein were combined with Laemmli buffer and incubated at 70°C for 10 min, prior to loading onto a 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel (with 8% stacking gel). Electrophoresis was carried out at 100 V for 10 min and at 200 V for the remainder of the separation. Proteins in the gel were then transferred to a 0.22 lm nitrocellulose membrane (GE Healthcare, Little Chalfont, Buckinghamshire, UK) using a Bio-Rad Trans-Blot â SD semi-dry transfer cell at 25 V for 40 min. To prevent non-specific antibody binding, the membrane was blocked for 2 h at room temperature in LI-COR Odyssey â blocking buffer reagent in PBS. FABP5 was detected using a rabbit polyclonal antibody (1 : 500 v/v dilution), and donkey anti-rabbit secondary antibody (1 : 30 000 v/v dilution). b-actin was detected using a mouse polyclonal antibody (1 : 1000 v/v dilution), and goat anti-mouse secondary antibody (1 : 15 000 v/v dilution). The membrane was imaged using a LI-COR Odyssey scanner. The image was analyzed using ImageJ (U. S. National Institutes of Health, Bethesda, MD, USA).
Animals and diet components
All animal experiments were approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee (MIPS.2012.46) and performed in accordance with the National Health and Medical Research Council guidelines for the care and use of animals for scientific purposes. This study was not pre-registered. Sample size calculations were performed employing a calculation program available from http://www.openepi.com/SampleSize, with 95% confidence interval and 80% power for studies comparing two groups. Male C57BL/6 mice (6-8 weeks old) were allocated into two groups by simple randomization (a number was generated for each mouse by computer). Mice with an even number were fed a standard AIN93G rodent diet (referred to as control diet) and mice with odd number were fed a 0.6% w/w DHA semi-pure rodent diet (referred to as DHA-enriched diet) (Specialty Feeds, Glen Forrest, WA, Australia). The DHA-enriched diet was modified from the control diet, by inclusion of tuna oil, giving 0.6% w/w DHA. The fatty acid composition for both diets is shown in Table 1 . A diet containing 0.6% w/w DHA reduced AD pathology in Tg2576 mice (over-expressing Ab) in a previous study (Lim et al. 2005) , and therefore this level of DHA was used in this study to assess whether a dietary intervention previously shown to reduce AD pathology could be associated with increased brain microvascular expression of FABP5. Mice were housed as a group of 4 in a tinted open top mouse cage, kept under a 12 : 12-h reverse light-dark cycle (lights on at 7 pm), with food and water provided ad libitum at 21 AE 2°C. Welfare-related assessments were performed daily according to animal ethics requirements.
Detection of FABP5 expression in mouse brain capillaries
Following the 21 day dietary intervention, mice would be used to either (i) measure FABP5 expression in cerebral microvessels, (ii) quantify brain endogenous DHA levels or (iii) assess BBB transport of 14 C-DHA as a measure for FABP5 function. An independent researcher assigned each mouse with a number, and the experimenter was blinded to the type of diet the animal consumed at the point of sample processing, perfusion, or data analysis. Capillary depletion was performed as reported in a previous study (Pan et al. 2015b) . Briefly, brain cortical tissue was isolated and homogenized in DMEM. BSA was added to achieve a final concentration of 15% w/v, and the mixture was centrifuged at 2000 g for 30 min at 4°C. The pellet (capillary fraction) was collected and rinsed with DMEM twice to remove excess BSA. Total proteins were extracted from the capillary pellet using two freeze-thaw cycles and 2 9 30 s sonication at 12 V. The total protein concentration was estimated using a NanoDrop â 1000 Spectrophotometer (Thermofisher) by recording the absorbance at a wavelength of 280 nm according to the manufacturer's instructions. The concentration of FABP5 was monitored using ELISA (DL Sci&Tech Development, Wuxi, Jiangsu, China), as detailed previously (Pan et al. 2015b ) and normalized to total protein concentration.
Endogenous brain DHA analysis
Total lipids (esterified and non-esterified) were extracted from the brain cortex and prepared as methylesters (FAME) for gas chromatography according to a published method (Fraser et al. 2008) . Methyl nonadecanoate (C19:0ME) was used as internal standard (IS) for quantitative analysis. Briefly, 50 mg of brain cortex was covered by 350 lL of ice-cold methanol and homogenized in a mechanical homogenizer (IKA â T25 digital ULTRA-TURRAX â ; Thermo Fisher Scientific) twice at 6000 rpm for 30 s. The sample was vortex mixed with 350 lL of chloroform containing 100 mg/L butylated hydroxytoluene (BHT) and IS. A further 150 lL of chloroform/ BHT : methanol 2 : 1 v : v was used to rinse the blade of the homogenizer. After 5 min centrifugation at 2000 g the supernatant of the sample was collected. Chloroform/BHT : methanol 1 : 1 v : v (200 lL) was used to resuspend the pellet prior to re-centrifugation. The supernatant was collected and combined with the supernatant collected from the previous centrifugation. After adding a further 400 lL of chloroform/BHT and 325 lL 0.9% w/v potassium chloride, the solution was vortexed and centrifuged. The lipid fraction (the lower chloroform phase) was collected and dried under N 2 . The samples were dissolved in 250 lL of 1 M ethanolic potassium hydroxide, and were left overnight at room temperature in a sealed tube. On the second day, a volume of 1250 lL of MilliQ water and 400 lL of hexane : diethyl ether 1 : 1 v : v containing 100 mg/L BHT was added to the sample. The solution was vortexed, centrifuged as above and the upper phase discarded. The addition of hexane : diethylether/BHT, vortexing, centrifugation, and removal of the upper phase were repeated three times. Concentrated HCl was used to adjust the pH of the lower phase to 3. A 400 lL volume of diethyl ether/BHT was added prior to vortexing, centrifugation, and removal of the upper phase. This step was repeated twice, and the lower phase was discarded. The two upper phases containing the free fatty acids derived from the lipid extract were combined and dried under N 2 .
Methylesters of the free fatty acids (FAME) were prepared in a sealed tube using 2.5% v/v concentrated sulfuric acid in anhydrous methanol overnight at room temperature. The solution was mixed with 1.5 mL of MilliQ water and 500 lL of hexane prior to vortexing. FAME were collected from the top hexane layer and diluted 10-fold prior to gas chromatography injection. FAME detection using GC-FID was undertaken as previously described (Pan et al. 2016) . All sample measurements were made in triplicate. Data were processed using Chemstation software (Agilent, Santa Clara, CA, USA). FAME peaks were identified according to the retention time and elution order of the authentic FAME standards. The cortical levels of fatty acids were presented as FAME peak normalized by IS peak and brain weight. In addition, all DHA/IS data were normalized by the average value of the brain DHA levels from mice fed a control diet.
Measurement of BBB transport of 14 C-DHA After the 21-day dietary intervention, in situ transcardiac perfusion was performed, as previously described (Pan et al. 2015b) , to determine whether DHA supplementation modified the BBB transport of 14 C-DHA. Briefly, the thorax of anesthetized mice (via ketamine/xylazine intraperitoneal injection) was cut open and the descending thoracic aorta clamped. The left and right jugular veins were severed, and the mice were perfused with 37°C Krebs carbonate-buffered physiologic saline (KBR) for 1 min and then KBR containing 14 C-DHA (0.5 lCi/mL) for 1 min at 10 mL/min. All perfusions were terminated by decapitating the animal and the whole brain was harvested. Sample preparation, radioactivity detection, and brain-to-perfusate ratio calculations (with vascular volume subtraction) were performed as previously described (Pan et al. 2015b ). No data Trace EPA 20:5 n-3
No data 0.14 DHA 22:6 n-3
No data 0.6 Total n-3 1.0 1.5 Total n-6 1.5 1.2 Total mono unsaturated fats 4.0 3.4 DHA, docosahexaenoic acid. Data are presented as g per 100 g of rodent diet, provided by the manufacturer. n-3: omega-3, n-6: omega-6.
concentration of cold-DHA used in this study is limited by the highest tolerable DHA concentration by endothelial cells, as well as being lower than physiological plasma DHA levels in mice fed a DHA-enriched diet (Wood et al. 2010) . The MBECs were isolated according to a published procedure (Pan et al. 2016) . Briefly, brain cortices were removed from C57BL/6 mice (9-11 weeks) and homogenized in DMEM using a Dounce homogenizer (Tissue Grinder, Potter-ELV; Wheaton Industries, Millville, NJ, USA). The brain homogenate was pelleted down by centrifugation at 1000 g. Subsequently, the pellet was resuspended in DMEM containing 1% w/v collagenase type II and DNase I (39 U/mL), and incubated at 37°C for 90 min prior to centrifugation at 2000 g for 20 min. The capillary-enriched fraction was separated from the rest of the brain homogenate (e.g. myelin) using 15% w/v BSA in DMEM with 2000 g centrifugation for 30 min. The capillary-enriched pellet was resuspended in DMEM and filtered through a 70 lm nylon mesh (BD Biosciences, Franklin Lakes, NJ, USA) to remove large blood vessels. The flow-through was centrifuged and resuspended with complete MBEC media (i.e., supplemented EBM-2 media) and seeded onto 24-well transwell inserts, coated with 1% v/v rat tail collagen Type I in PBS. The cells were incubated at 37°C (5% CO 2 /95% O 2 ) overnight, prior to puromycin treatment (3 lg/ mL in complete MBEC media to eliminate non-MBECs) for 72 h. At the end of puromycin treatment, fresh media was replaced and complete media changes were performed every 2 days. The trans-endothelial electrical resistance was monitored from days 5-7 using an EVOM-endohmeter (World Precision Instruments, Sarasota, FL, USA). Transwell inserts with transendothelial electrical resistance value > 50 Ocm 2 on day 7 were selected for permeability studies. On day 7, cells were incubated either with blank EBM-2 basal media (transport medium) or 50 lM DHA in transport medium at 37°C in a humidified incubator (5% CO 2 /95% O 2 ) 1 h before the commencement of the permeability study. To commence permeability studies, 0.5 lCi of 14 C-DHA was added to the apical chamber. A 10 lL aliquot of the apical chamber was taken at time 0, and a 20 lL sample was taken from the receptor chamber at 15 min. All samples were measured for radioactivity in a Tri-Carb 2800TR liquid scintillation counter (PerkinElmer), from which the % 14 C-DHA in the receptor chamber at the end of the permeation study was then calculated.
Statistical analysis
Data analysis was performed using Prism software (GraphPad, La Jolla, CA, USA). Data outliers were defined as any data deviating from the average value by 39 SD. The comparisons between experimental and control groups were evaluated by Student's unpaired t-tests. ANOVA comparisons were used followed by post hoc analyses where appropriate. Statistical significance was set at a value of p < 0.05. All data are expressed as mean AE SEM.
Results
DHA increases FABP5 mRNA and protein expression in hCMEC/D3 cells
The impact of DHA on FABP5 expression was studied using hCMEC/D3 cells, an in vitro BBB model commonly used to investigate BBB protein expression. The highest DHA concentration tolerated by hCMEC/D3 cells was found to be 50 lM for 24 h (Fig. 1a) , and 12.5 lM for 48-h treatment (Fig. 1b) . In addition, hCMEC/D3 cells could tolerate 12.5 lM DHA treatment for 72 h (Fig. 1c) . A 2.1-fold increase in FABP5 mRNA was observed in hCMEC/D3 cells treated with 50 lM DHA for 24 h (Fig. 2a) , however, no FABP5 protein up-regulation was detected in these cells (Fig. 2b) . For a 48 h treatment with 12.5 lM DHA, a 42.9 AE 13.4% elevation in FABP5 mRNA was observed (Fig. 2c) and this was associated with a 20.2 AE 5.2% increase in FABP5 protein (Fig. 2d) . A FABP5 upregulatory effect was also achieved by a 72 h treatment with 12.5 lM DHA, where a 36.7 AE 12.0% elevation in FABP5 protein was observed (Fig. 2e) . A 24 h treatment with 50 lM OA (a tolerable treatment demonstrated by MTT, Fig. 3a ) did not affect FABP5 mRNA expression in hCMEC/ D3 cells (Fig. 3b) .
Dietary DHA supplementation elevates BBB expression of FABP5 protein and brain DHA levels The impact of dietary DHA supplementation on FABP5 expression at the BBB was examined by feeding C57BL/6 mice with a DHA-enriched diet for 21 days. A significant (p < 0.01) effect of diet on FABP5 protein expression in the brain microvessels was revealed, with the DHA-enriched diet leading to a 70.4 AE 13.1% elevation in FABP5 protein expression (Fig. 4a) . Associated with this increase in FABP5 expression was a significant elevation (28.7 AE 9.8%, p < 0.05) in the cortical DHA levels in mice fed the DHAenriched diet compared to that in the mice fed the control diet (Fig. 4b ). An elevation in the cortical levels of palmitic acid (23.7 AE 10.2%, p < 0.05) was also observed (Table 2) .
Dietary DHA supplementation reduces the rate of 14 C-DHA transport across the BBB Given that FABP5 is involved in the BBB transport of DHA, we hypothesized that increased FABP5 expression at the BBB would lead to increased BBB transport of 14 C-DHA. Surprisingly, however, a significant reduction (36.0 AE 15.5%, p < 0.05) in the BBB transport of 14 C-DHA was observed over a 1-min period in mice fed the DHA-enriched diet compared to the control mice (Fig. 5a) . Therefore, while DHA increased FABP5 expression at the BBB and endogenous brain levels of DHA, the rate at which DHA traffics across the BBB over a very short period of time (1 min) was reduced. One possible explanation for this observation is that the presence of very high levels of DHA within the cerebral microvasculature may have interfered with the BBB transport of (Fig. 5b) .
Discussion
DHA is an n-3 PUFA with cognitive benefits and the levels of this fatty acid are reduced in the brains of individuals with AD (Nakada et al. 1990; S€ oderberg et al. 1991; Guan et al. 1999) . It has been reported to reduce pathology associated with AD, including a reduction in beta-amyloid, hyperphosphorylated tau, and neuroinflammation, ultimately improving cognitive function in rodent models of AD (Arsenault et al. 2011; Teng et al. 2015) . For this reason, DHA supplementation has been used in individuals with AD, and an improvement in cognitive function has been reported in mild cognitive impairment and early AD, with limited effectiveness in late-stage AD (Freund-Levi et al. 2006; Sinn et al. 2012; Pan et al. 2015a) . The reason behind the lower brain levels of DHA in AD are not very clear; however, given that the brain has limited ability to synthesize its own DHA and the majority of brain DHA is derived from plasma sources (Rapoport et al. 2001 (Rapoport et al. , 2007 , observations of reduced BBB trafficking of DHA in mouse models of AD (Calon 2011; Pan et al. 2018) suggest that reversing BBB dysfunction associated with DHA trafficking in AD could hold therapeutic potential. We have demonstrated that the levels of a key BBB trafficking protein FABP5 are diminished in a mouse model of AD (Pan et al. 2018) and postulate that approaches aimed at increasing the levels of FABP5 could restore brain DHA levels in AD. As DHA itself can affect PPAR activation and PPAR activation may be involved in regulation of FABP5 (Armstrong et al. 2014) , it is possible that DHA itself can modify the BBB expression of FABP5, ultimately enhancing its own brain uptake. It is known in other tissues and organs that dietary fatty acids can affect the expression of FABP (Poirier et al. 1997; Hoekstra et al. 2006; Trevaskis et al. 2011; Elsherbiny et al. 2015) , however, the impact of DHA dietary supplementation on the BBB has not been studied elsewhere. Therefore, this study investigated the impact of dietary DHA supplementation on the BBB expression of FABP5, BBB transport of exogenous DHA, and endogenous brain levels of DHA.
To demonstrate the potential FABP5 up-regulatory effect of DHA, hCMEC/D3 cells were treated with tolerable DHA concentrations (50 lM for 24 h, 12.5 lM for 48 and 72 h), and FABP5 mRNA expression and protein up-regulation was observed. It is possible that increased FABP5 expression in hCMEC/D3 cells would lead to elevated DHA cellular uptake, given that an increase in 14 C-DHA uptake by COS7 cells with FABP5 over-expression has been reported (Pan et al. 2016) . The response of FABP5 to DHA suggests that FABP5 may play an important role in protection against the cellular toxicity of reactive lipids (including DHA) through transporting them into intracellular compartments (Hoekstra et al. 2006) . However, the mechanism DHA utilizes to enhance FABP5 expression at the BBB is not clearly understood. It is possible that binding of DHA to FABP5 could stabilize the ligand-sensitive tertiary nuclear localization signal located on the a1 and a2 helices of FABP5 (i.e., active conformation). The FABP5 with the nuclear localization signal stabilized by the DHA would subsequently enter the nucleus and activate PPARb/d to enhance the transcription of FABP5 gene (Morgan et al. 2010) . This proposed mechanism is supported by a previous report, where the ability of ligand to stabilize the active conformation of FABP4 has been demonstrated (Gillilan et al. 2007) , and PUFAs containing a cis-double bond could stabilize the active conformation of FABP5 (Armstrong et al. 2014) . Our observation that 50 lM DHA but not OA for 24 h elevated FABP5 mRNA expression would also lend support to this proposed mechanism, given that DHA is cis-bonded PUFA but OA is not. As an alternative mechanism, the exogenous DHA supplied to hCMEC/D3 cells could result in generation of oxylipins (Aukema et al. 2016) , which are known to interact with PPAR pathway (Barquissau et al. 2017) , and therefore increase the expression of FABP5 and possibly other genes that encode for additional proteins involved in DHA uptake, such as fatty acid transporters (Murphy 2017) . For example, PPAR activation may also up-regulate the expression of fatty acid transporter 1, as the FATP1 gene is under the control of PPAR agonism in liver and adipose tissue (Martin et al. 2000; Wierzbicki et al. 2009 ). To support this possibility, the levels of FATP1 and FATP4 in hCMEC/D3 cells were measured following exposure to DHA, and a 1.53-fold and 1.45-fold up-regulation was observed, respectively ( Figure S1 ). FATP1 and FATP4 have been previously shown to mediate uptake of DHA (Murphy 2017) , and therefore, any effects of dietary DHA on fatty acid uptake could be a result of both increased expression of the cytoplasmic carrier protein FABP5 and the membrane transporters, FATP1 and FATP4. Upon demonstrating that DHA enhances FABP5 expression in hCMEC/D3 cells, C57BL/6 mice were fed either a control diet or a DHA-enriched diet for 21 days to determine the effect of dietary DHA supplementation on FABP5 expression at the BBB. This period of intervention was selected based on observations that FABP5 responses to fatty diet is time-dependent, with the greatest increase observed after 2 weeks (Hoekstra et al. 2006) , and elevations in plasma DHA being observed after a 3-week DHA supplementation regime in humans (Vandal et al. 2008) . A 1.7-fold increase in brain microvascular FABP5 expression was identified in mice fed the DHA-enriched diet, compared to the control group, which is in agreement with a previous protein expressed in the brain microvessels isolated from C57BL/6 mice after a 21-day treatment with a control diet or docosahexaenoic acid (DHA)-enriched diet (n = 3-4), where the brain microvascular FABP5 expression was increased 1.7-fold in mice fed a DHA-enriched diet comparing to those fed a control diet. N represents number of microvessel isolations, with each isolation using 3-4 mouse brains. (b) Relative brain cortical total DHA levels (normalized to the control group) in the C57BL/6 mice fed a control and a DHA-enriched diet for 21 days (n = 3), with a 1.3-fold increase in DHA levels observed in mice fed a DHA-enriched diet. N represents number of animals. Data are presented as mean AE SEM, with *p < 0.05, **p < 0.01. study, where spinal cord FABP5 gene expression elevated twofold in rats fed a DHA-enriched diet for 8 weeks (Figueroa et al. 2016) . The higher fold increase in FABP5 expression observed in the mouse dietary intervention study than the in vitro study could be explained by the longer term of exposure to higher levels of DHA. Associated with this increase in brain microvascular FABP5 expression was a 1.3-fold increase in brain cortical DHA levels. Similarly, elevated brain DHA levels (23.7 AE 5.1%) were observed by Ouellet et al. in an 18-month dietary intervention study. Our 21 day dietary study resulted in similar elevations in cortical brain DHA levels to the Ouellet study (540 days), suggesting that brain DHA levels can reach their maximum increase after weeks, although a direct experimental comparison between our 21-day and the 540-day intervention has not been made. It should be noted that the increase in brain DHA levels cannot be solely attributed to increased BBB expression of FABP5, as it is possible that other factors affecting DHA transport, such as FATP1, FATP4, and Mfsd2a are also increased as a result of DHA intervention. Indeed, we have demonstrated that the levels of FATP1 and FATP4 were increased 1.53-fold and 1.45-fold, respectively, in hCMEC/D3 cells following DHA exposure ( Figure S1 ). While the expression of FATP1 and FATP4 were not measured in vivo, it is likely that the BBB expression of these membrane transporters are also increased with dietary DHA supplementation, given the clear correlation between FABP5 up-regulation following DHA exposure both in vitro and in vivo. However, further studies would be required to confirm that DHA indeed increases the BBB expression of FATP1 and FATP4 in vivo. The in vitro studies, however, are in agreement with the concept that FATP1, FATP4, and FABP5 may work as a comprehensive DHA transport mechanism at the BBB (Murphy 2017) . Given that plasma non-esterified DHA is the major pool supplying the brain (Chen et al. 2015) , Mfsd2a was not included in this study, as it is involved in the BBB transport of esterified DHA (Nguyen et al. 2014) .
The association between increased FABP5 and elevated brain DHA levels is in line with our previous study showing decreased FABP5 (in FABP5-deficient mice) was associated with reduced brain DHA levels. In addition to an increase in DHA brain levels, the DHA intervention led to a significant increase in brain palmitic acid levels. The increased palmitic acid levels in the brain are possibly a result of a twofold increase in the availability of palmitic acid from the DHAenriched diet compared with the control diet. As a result of high affinity of FABP5 to palmitic acid (comparable to DHA) (Liu et al. 2008) , increased BBB transport of palmitic acid is possible, which needs to be confirmed by further study.
Given that FABP5 is involved in the BBB transport of DHA, the impact of a DHA-enriched diet on the transport of 14 C-DHA was studied. Elevated FABP5 expression in brain microvessels was associated with a lower BBB transport of 14 C-DHA demonstrated by in situ transcardiac perfusion. This result appears to be inconsistent with our previous findings where we have demonstrated that 14 C-DHA transport across the BBB is reduced in FABP5-deficient mice (Pan et al. 2015b) , and that 14 C-DHA uptake is increased in COS-7 cells transfected with hFABP5 relative to nontransfected cells (Pan et al. 2016 ). In the previous study, the systems were devoid of competing DHA and other fatty acids (which are likely present in the high DHA-containing diet), and it is likely that these dietary fatty acids could be present within the brain microvasculature at high levels during the measurement of the BBB transport of 14 C-DHA in vivo, competing with 14 C-DHA for FABP5 during the perfusion, leading to a lower apparent B : P ratio despite FABP5 being up-regulated. This competitive mechanism proposed could also explain the findings from Ouellet et al., where lower BBB transport of DHA was demonstrated in mice fed a DHA enriched diet over 18 months (Ouellet et al. 2009 ). To confirm this, we undertook in vitro studies where we assessed the impact of cold-DHA on the rate of transport C-DHA across MBEC monolayers pre-incubated with cold-DHA for 1 h (where FABP5 was likely saturated with the high concentrations of cold-DHA) was significantly reduced, suggesting that high levels of DHA likely to be present in the brain microvasculature might decrease the apparent rate of 14 C-DHA transport across the BBB, albeit the overall CNS exposure of DHA is increased over a 21 day period. Indeed, mice fed a DHA-enriched diet (with sixfold higher n-3 fatty acid content compared to control diet) has led to a threefold increase in plasma DHA levels (Wood et al. 2010) , lending support to the possibility that FABP5 at the BBB could be saturated by DHA despite the FABP5 up-regulation in this study. In order to more appropriately determine if increasing FABP5 expression leads to increased BBB transport of 14 C-DHA and increased CNS exposure, FABP5 expression could be enhanced in the absence of competing fatty acid ligands. It has been reported that GW0742 treatment (PPARb/d selective ligand) resulted in up-regulation of FABP5 mRNA and protein in human prostate cancer cell lines (PC3M) (Morgan et al. 2010) , and therefore, such an approach could be used to assess whether FABP5 up-regulation does indeed lead to increased BBB transport of DHA in the absence of large concentrations of competing fatty acids. Although, other possible mechanisms (e.g., FATP1, FATP4, Msdf2a) governing BBB transport DHA should not be neglected, and such mechanisms could be affected by dietary intervention, as discussed above.
In summary, the ability of DHA to up-regulate FABP5 expression at the BBB has been demonstrated in vitro and in vivo, and this was associated with increased expression of the membrane transporters FATP1 and FATP4 in vitro. There appears to be an inverse relationship between DHA transport and endogenous DHA levels with FABP5 expression, but this could be confounded by high levels of dietary fatty acids in the system, which interfere with the 14 C-DHA in situ perfusion study. Pharmacological up-regulation of FABP5 in the absence of high levels of competing fatty acids (as occurs with a DHA-enriched diet) may allow the identification of a clear relationship between FABP5 upregulation, DHA transport across the BBB and endogenous brain levels of DHA. Up-regulating FABP5 expression at the BBB could be a novel way to enhance the brain levels of DHA, which might serve as a potential treatment for AD.
